Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Zhiwu Tan, Mei Sum Chiu, Xinxiang Yang, Ming Yue, Tan To Cheung, Dongyan Zhou, Yuewen Wang, Anthony Wing-Hung Chan, Chi Wing Yan, Ka Yi Kwan, Yik Chun Wong, Xin Li, Jingying Zhou, Ka Fai To, Jiye Zhu, Chung Mau Lo, Alfred Sze-Lok Cheng, Stephen Lam Chan, Li Liu, You-Qiang Song, Kwan Man, Zhiwei Chen
OBJECTIVE: Immune checkpoint blockade (ICB) has improved cancer treatment, yet why most hepatocellular carcinoma (HCC) patients are resistant to PD-1 ICB remains elusive. Here, we elucidated the role of a programmed cell death protein 1 (PD-1) isoform, Δ42PD-1, in HCC progression and resistance to nivolumab ICB. DESIGN: We investigated 74 HCC patients in three cohorts, including 41 untreated, 28 treated with nivolumab and 5 treated with pembrolizumab. Peripheral blood mononuclear cells from blood samples and tumour infiltrating lymphocytes from tumour tissues were isolated for immunophenotyping...
November 30, 2022: Gut
#2
JOURNAL ARTICLE
John Gásdal Karstensen, Srdan Novovic, Erik Feldager Hansen, Annette Bojer Jensen, Henrik Lovendahl Joergensen, Morten Laksafoss Lauritsen, Mikkel Parsberg Werge, Palle Nordblad Schmidt
OBJECTIVE: In treating pancreatic walled-off necrosis (WON), lumen-apposing metal stents (LAMS) have not proven superior to the traditional double pigtail technique (DPT). Among patients with large WON (>15 cm) and their associated substantial risk of treatment failure, the increased drainage capacity of a novel 20-mm LAMS might improve clinical outcomes. Hence, we conducted a study comparing the DPT and 20-mm LAMS in patients with large WON. DESIGN: A single-centre, open-label, randomised, controlled superiority trial using an endoscopic step-up approach in patients with WON exceeding 15 cm in size...
November 29, 2022: Gut
#3
JOURNAL ARTICLE
Jessica Roelands, Manon van der Ploeg, Marieke E Ijsselsteijn, Hao Dang, Jurjen J Boonstra, James C H Hardwick, Lukas J A C Hawinkels, Hans Morreau, Noel F C C de Miranda
OBJECTIVE: Biological insights into the stepwise development and progression of colorectal cancer (CRC) are imperative to develop tailored approaches for early detection and optimal clinical management of this disease. Here, we aimed to dissect the transcriptional and immunologic alterations that accompany malignant transformation in CRC and to identify clinically relevant biomarkers through spatial profiling of pT1 CRC samples. DESIGN: We employed digital spatial profiling (GeoMx) on eight pT1 CRCs to study gene expression in the epithelial and stromal segments across regions of distinct histology, including normal mucosa, low-grade and high-grade dysplasia and cancer...
November 28, 2022: Gut
#4
LETTER
Anastasia A Minervina, Mikhail V Pogorelyy, Steffen Paysen, Ulrich Luening, Frauke Degenhardt, Andre Franke, Paul G Thomas, Elisa Rosati
No abstract text is available yet for this article.
November 25, 2022: Gut
#5
JOURNAL ARTICLE
Daniel von Renteln, Roupen Djinbachian, Melissa Zarandi-Nowroozi, Mahsa Taghiakbari
No abstract text is available yet for this article.
November 21, 2022: Gut
#6
LETTER
Emad Mansoor, Scott A Martin, Abe Perez, Vu Quang Nguyen, Jeffry Katz, Shubham Gupta, Fabio Cominelli
No abstract text is available yet for this article.
November 21, 2022: Gut
#7
LETTER
Jan Bornschein, D Mark Pritchard, Peter Malfertheiner
No abstract text is available yet for this article.
November 15, 2022: Gut
#8
LETTER
Edith Lahner, Emanuele Dilaghi, Ludovica Dottori, Bruno Annibale
No abstract text is available yet for this article.
November 10, 2022: Gut
#9
JOURNAL ARTICLE
Zhihui Duan, Dengxiang Liu, Shengyun Zhou, Hui Li, Xiaofang Sun, Chunqian Zhao, Qiong Duan, Liwei Li, Xiaochong Zhang, Lingxuan Jin
No abstract text is available yet for this article.
November 9, 2022: Gut
#10
LETTER
Zhuangzhuang Shi, Guoru Hu, Min W Li, Lei Zhang, Xin Li, Ling Li, Xinhua Wang, Xiaorui Fu, Zhenchang Sun, Xudong Zhang, Li Tian, Zhaoming Li, Wei-Hua Chen, Mingzhi Zhang
No abstract text is available yet for this article.
November 8, 2022: Gut
#11
LETTER
Christoph Roderburg, Karel Kostev, Alexander Mertens, Tom Luedde, Sven H Loosen
No abstract text is available yet for this article.
November 8, 2022: Gut
#12
JOURNAL ARTICLE
Jasmohan S Bajaj, Marcela Peña-Rodriguez, Alex La Reau, Wendy Phillips, Michael Fuchs, Brian C Davis, Richard K Sterling, Masoumeh Sikaroodi, Andrew Fagan, Amirhossein Shamsaddini, Zachariah Henseler, Tonya Ward, Puneet Puri, Hannah Lee, Patrick M Gillevet
OBJECTIVE: First decompensation development is a critical milestone that needs to be predicted. Transkingdom gut microbial interactions, including archaeal methanogens, may be important targets and predictors but a longitudinal approach is needed. DESIGN: Cirrhosis outpatients who provided stool twice were included. Group 1: compensated, group 2: 1 decompensation (decomp), group 3: >1 decompensationwere followed and divided into those who remained stable or decompensated...
November 7, 2022: Gut
#13
LETTER
Manuel Zorzi, Jessica Battagello, Claudio Barbiellini Amidei
No abstract text is available yet for this article.
November 4, 2022: Gut
#14
JOURNAL ARTICLE
Patrice D Cani, Claude Knauf
No abstract text is available yet for this article.
November 4, 2022: Gut
#15
LETTER
Thierry Thevenot, Maxime Desmarets, Delphine Weil, Vincent Di Martino
No abstract text is available yet for this article.
November 3, 2022: Gut
#16
LETTER
Emad Mansoor, Scott A Martin, Abe Perez, Vu Quang Nguyen, Jeffry A Katz, Shubham Gupta, Fabio Cominelli
No abstract text is available yet for this article.
November 2, 2022: Gut
#17
LETTER
Christopher Vélez, Laura E Targownik
No abstract text is available yet for this article.
November 2, 2022: Gut
#18
JOURNAL ARTICLE
Neelendu Dey
No abstract text is available yet for this article.
November 2, 2022: Gut
#19
JOURNAL ARTICLE
Chao-Yang Meng, Shiyu Sun, Yong Liang, Hairong Xu, Chao Zhang, Min Zhang, Fu-Sheng Wang, Yang-Xin Fu, Hua Peng
OBJECTIVE: The purpose of this study is to develop an anti-PDL1-based interferon (IFN) fusion protein to overcome the chronic hepatitis B virus (HBV)-induced immune tolerance, and combine this immunotherapy with a HBV vaccine to achieve the functional cure of chronic hepatitis B (CHB) infection. DESIGN: We designed an anti-PDL1-IFNα heterodimeric fusion protein, in which one arm was derived from anti-PDL1 antibody and the other arm was IFNα, to allow targeted delivery of IFNα into the liver by anti-PDL1 antibody...
October 31, 2022: Gut
#20
LETTER
Nan Wang, Mingyue Cheng, Kang Ning
No abstract text is available yet for this article.
October 28, 2022: Gut
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
